Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010346 | 0.90 | CA12 (0.48) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL11490700 | 0.88 | GPR88 (0.42) | MEN1KMT2AALDH1A1CYP3A4HTT | |
| SCHEMBL3227491 | 0.86 | CYP2D6 (0.50) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL11399910 | 0.86 | CA12 (0.56) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL6386316 | 0.84 | BCHE (0.50) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL3140878 | 0.84 | CA1 (0.43) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL4010343 | 0.84 | CA12 (0.43) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL17871716 | 0.83 | GAA (0.49) | MEN1KMT2AALDH1A1GAACYP1A2 | |
| SCHEMBL19665104 | 0.83 | ACHE (0.46) | MEN1KMT2AALDH1A1CYP3A4MAPT | |
| SCHEMBL28888567 | 0.83 | CA12 (0.48) | MEN1KMT2ACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110828-B1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | UNIV SZEGEDI (HU) | 2020-12-09 | — | — | EP | claimed |
| EP-3110828-A1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | Szegedi Tudományegyetem (HU) | 2017-01-04 | — | — | EP | claimed |
| WO-2015128687-A1 | CONTINUOUS FLOW PEPTIDE SYNTHESIS | Szegedi Tudományegyetem (HU) | 2015-09-03 | — | — | WO | claimed |
| JP-2273698-A | — | — | None | — | — | JP | disclosed |
| JP-2273696-A | — | — | None | — | — | JP | disclosed |
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| EP-3630147-B1 | PEPTIDE PAC1 ANTAGONISTS | AMGEN INC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4685154-A1 | POLYPEPTIDE DERIVED FROM TRIDEGIN | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | disclosed |
| US-11643440-B2 | Peptide PAC1 antagonists | AMGEN INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-1992022571-A1 | IMMUNOASSAY FOR NON-A NON-B HEPATITIS | BAXTER DIAGNOSTICS INC. (US) | 1992-12-23 | — | — | WO | disclosed |
| WO-1992017612-A1 | ASSAY FOR NON-A NON-B HEPATITIS | BAXTER DIAGNOSTICS INC. (US) | 1992-10-15 | — | — | WO | disclosed |
| US-5112947-A | Oligopeptides, nootropic agents | NIPPON CHEMIPHAR CO., LTD. (JP) | 1992-05-12 | — | — | US | disclosed |
| WO-1992005271-A1 | PROCESS FOR THE PREPARATION OF C-TERMINALLY AMIDATED PEPTIDES | BUCHARDT OLE (DK) | 1992-04-02 | — | — | WO | disclosed |
| JP-H02273696-A | PEPTIDE AND ANTIDEMENTIAL AGENT CONTAINING THE SAME | NIPPON CHEMIPHAR CO LTD | 1990-11-08 | — | — | JP | disclosed |
| JP-H02273698-A | PEPTIDE AND ANTIDEMENTIAL AGENT CONTAINING THE SAME | FUJIREBIO INC | 1990-11-08 | — | — | JP | disclosed |
| EP-0393934-A1 | Novel peptides, and antidementia agents containing the same | NIPPON CHEMIPHAR CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4965343-A | COUPLING SIDE-CHAIN UNPROTECTED HYDROXYAMINO ACIDS TO PEPTIDE CHAIN USING BENZOTRIAZOL-1-YL-OXY-TRIS-(DIMETHYL)-OXY-TRIS-(DIMETHYL)-PHOSPHONIUM HEXAFLUOROPHOSPHATE | HOFFMANN-LA ROCHE INC. (US) | 1990-10-23 | — | — | US | disclosed |
| US-4478984-A | CONDENSING AN N-(CHLOROBENZYL)-PHTHALIMIDE WITH A STYRENE RESIN AND SPLITTING THE IMIDE | SMITHKLINE BECKMAN CORPORATION (US) | 1984-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | MEN1 1171/4885KMT2A 2504/4885CA12 1734/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | MEN1 416/4885KMT2A 3479/4885CA12 1554/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | MEN1 1297/4885KMT2A 2277/4885CA12 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.